LAS VEGAS, Sept. 22, 2020 /PRNewswire/ -- JanOne Inc.
(Nasdaq: JAN), a company focused on developing treatments for
conditions that cause severe pain and drugs with non-addictive,
pain-relieving properties, today announced that the Company has
issued its September 2020 Shareholder Letter. The letter
highlights JanOne's recent updates on the Company's corporate and
clinical developments.
Recent Company Highlights include:
- Obtained FDA authorization for the transfer of an
investigational new drug (IND) for the Company's sodium nitrite
tablets
- Completed stable formulation and engineering of JAN101 for GMP
(Good Manufacturing Practice) manufacturing to support its planned
Phase 2b PAD study
- Hired Eurofins Alphora as a bottling and labeling partner to
support upcoming clinical trials
- Appointed Dr. Doug Flanagan as
Chief Formulation Advisor
- Added Dr. Rakesh Patel, Dr.
Timothy Ness, Dr. Alan Kaye and Dr. John
Cooke to the Scientific Advisory Board
"This has been an exciting, busy year for the Company as we have
transitioned into the flourishing biopharma industry – an area
which I believe holds tremendous promise. The initial path forward
is to continue the development of our proprietary, high-value,
late-stage asset, JAN101 for the treatment of peripheral artery
disease (PAD)," said Tony Isaac,
Chief Executive Officer of JanOne. "Additionally, we continue to
pursue additional indications for JAN101, like the recently
announced potential application for the treatment of vascular
complications associated with COVID-19. Despite the obstacles
created by the ongoing pandemic, I believe that through key
additions to our world-class team, strong partnerships and
leading-edge research and development, JanOne is ideally positioned
for a successful future."
To view the Company's Corporate Update Letter in its entirety,
please visit:
https://ir.janone.com/company-information/shareholder-letter
About JanOne
JanOne (NASDAQ: JAN) is focused on
developing treatments for diseases that cause severe pain. By
alleviating pain at the source, JanOne aims to reduce the need for
opioid prescriptions to treat disease associated pain that can lead
to opioid abuse. The company is also exploring solutions for
non-addictive pain medications. Its lead candidate JAN101 is for
treating peripheral artery disease (PAD), a condition that affects
over 8.5 million Americans. JAN101 demonstrated positive results in
a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021.
JanOne is dedicated to funding resources toward innovation,
technology, and education for PAD, associated vascular conditions
and neuropathic pain. JanOne continues to operate its legacy
businesses under their current brand names, which are undergoing
review to determine appropriate strategic alternatives.
For more information, visit janone.com
Forward-Looking and Cautionary Statements
This press
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. In accordance
with the safe harbor provisions of this Act, statements contained
herein that look forward in time that include everything other than
historical information, including statements relating to (i)
whether JAN101 can treat vascular complications in Covid-19
patients, (ii) whether the company can obtain FDA approval for its
Covid-19 study, (iii) when the Phase 2b trials for PAD commence, and (iv) when and
whether the company will submit an IND for the treatment of
Covid-19 vascular complications, and (v) when manufacturing of
JAN101 will commence. These forward-looking statements can be
identified by terminology such as "will," "aims," "expects,"
"anticipates," "future," "intends," "plans," "believes,"
"estimates" and similar statements. JanOne may also make written or
oral forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission (the "SEC") on Forms 10-K and
10-Q, Current Reports on Form 8-K, in its annual report to
stockholders, in press releases, and other written materials and in
oral statements made by its officers, directors or employees to
third parties. There can be no assurance that such statements will
prove to be accurate and there are a number of important factors
that could cause actual results to differ materially from those
expressed in any forward-looking statements made by the company,
including, but not limited to, plans and objectives of management
for future operations or products, the market acceptance or future
success of our products, and our future financial performance. The
company cautions that these forward-looking statements are further
qualified by other factors including, but not limited to, those set
forth in the company's Annual Report on Form 10-K for the fiscal
year ended December 28, 2019
(available at http://www.sec.gov). JanOne undertakes no obligation
to publicly update or revise any statements in this release,
whether as a result of new information, future events, or
otherwise.
Investor Relations & Media Contact
IR@Janone.com
1 (800) 400-2247
View original content to download
multimedia:http://www.prnewswire.com/news-releases/janone-issues-september-2020-shareholder-letter-updating-investors-on-recent-pharma-asset-potential-for-peripheral-artery-disease-301135730.html
SOURCE JanOne